Quantcast
Last updated on April 19, 2014 at 13:20 EDT

Latest Osteonecrosis of the jaw Stories

2011-06-01 00:24:00

EAST HANOVER, N.J., June 1, 2011 /PRNewswire/ -- Novartis Pharmaceuticals Corporation ("Novartis") will showcase data from 140 abstracts on its current oncology products and investigational agents at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO). These data underscore the company's commitment to developing treatments to improve the lives of patients with cancer. "Through our commitment to R&D and collaborations with the scientific and patient communities,...

2011-05-20 06:30:00

THOUSAND OAKS, Calif., May 20, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended a positive opinion for the marketing authorization of XGEVA(TM) (denosumab) for the prevention of skeletal-related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with bone metastases from solid tumors. If approved by the...

2011-05-11 00:00:27

The Rottenstein Law Group, which represents clients with claims stemming from the severe side effects of the drug Fosamax, is considering the likelihood of consolidation of federal lawsuits against manufacturer Merck for pretrial proceedings in light of recent opposition voiced by some plaintiffs. New York, NY (PRWEB) May 09, 2011 On March 23, 2011, Merck moved the Judicial Panel on Multidistrict Litigation (JPML) to consolidate all federal Fosamax lawsuits into a single Multidistrict...

2011-05-06 00:00:31

Fosamax®, a prescription osteoporosis drug for men and women has recently been linked by medical research, with weakened bones that can lead to spontaneous, low-energy bone breaks. The Spangenberg law firm is currently investigating potential lawsuits on behalf of current or former Fosamax users who have suffered from these unusual low-energy (or "atypical") bone fractures. Cleveland, OH (PRWEB) May 05, 2011 Recent medical research has linked Fosamax®, a prescription drug used to...

2011-04-12 10:40:00

NEW YORK, April 12, 2011 /PRNewswire-USNewswire/ -- The Bone and Cancer Foundation (BCF) provides information for cancer patients who have bone related complications including metastasis and cancer treatment induced bone loss. BCF patient publications cover very timely topics including Vitamin D and new treatment options, and are the only publications available that deal specifically with bone metastasis and cancer treatment induced bone loss. The following patient publications have been...

2011-04-12 00:00:29

The Rottenstein Law Group, which represents clients with claims stemming from the severe side effects of the drug Fosamax, is warning those whose doctors advise time off from taking the drug to speak with legal counsel sooner rather than later, because an interruption in dosing might not result in a pausing of the time to sue for harms caused by the medication. New York, NY (Vocus/PRWEB) April 11, 2011 Despite being the most popular osteoporosis treatment medication on the market, Fosamax...

2011-03-23 15:06:00

THOUSAND OAKS, Calif., March 23, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) today announced new long-term data showing that during the fourth and fifth years of Prolia® (denosumab) treatment, postmenopausal women with osteoporosis receiving Prolia continued with further, statistically significant, year-over-year increases in lumbar spine and total hip bone mineral density (BMD), a key measurement of bone strength. The overall adverse event profile was similar for the...

2011-03-23 15:05:00

THOUSAND OAKS, Calif., March 23, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) today announced new data that showed postmenopausal women with osteoporosis had significantly greater adherence, compliance, and persistence during Prolia® (denosumab) treatment than during alendronate treatment, an oral bisphosphonate commonly used to treat osteoporosis. Adherence to treatment, which includes both compliance (a measure of how well patients follow directions for taking...

2011-02-25 08:41:28

By: Rhonda Craig, Ivanhoe Health Correspondent (Ivanhoe Newswire)  -- An osteoporosis drug designed to improve bone health may be associated with femoral fractures. Bisphosphonates are a group of prescription medications used to treat bone loss in osteoporosis patients. But in this new study, researchers found that older women who used these medications for a longer period of time were more likely to experience atypical fractures. "We found that women who are 68 years or older, who take...

2011-02-24 18:05:00

THOUSAND OAKS, Calif., Feb. 24, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) today announced the publication of results from a Phase 3 head-to-head trial that compared XGEVA(TM) (denosumab) to Zometa(®) (zoledronic acid) in preventing bone complications called skeletal-related events (SREs) in 1,901 men with prostate cancer and bone metastases. The study, published in The Lancet, met its primary and secondary endpoints and demonstrated XGEVA's superiority compared to Zometa...